Quality Tested Third-Party Verified Highly Purified U.S. Based Expert Support
PhysIQ PeptidesPhysIQ Peptides
Back to Shop
CJC-1295 / Ipamorelin (No DAC) 5/5mg research peptide vialBlend

CJC-1295 / Ipamorelin (No DAC)

CJC-1295 (without DAC) with Ipamorelin

This research vial combines two growth hormone secretagogues that act through different receptors: CJC-1295 without DAC (also called Modified GRF 1-29), a GHRH receptor agonist, and ipamorelin, a selective ghrelin receptor (GHS-R1a) agonist, at 5 mg each.

Modified GRF (1-29) is the 29-residue active fragment of growth hormone-releasing hormone with four amino-acid substitutions that slow enzymatic breakdown compared with the parent sermorelin sequence. Ipamorelin is a pentapeptide GHRP known in the literature for selectively releasing growth hormone without the ACTH and cortisol responses seen with earlier GHRPs. Because the GHRH and ghrelin pathways converge on the same pituitary cells through different signaling routes, pairing the two is a common design in research on how they interact to shape GH pulses.

PhysIQ Peptides supplies this blend as a lyophilized powder, third-party tested for purity and identity, for in vitro and laboratory research use only.

Choose how to buy

Your first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.

$50.00per vial · 5/5mg
Ask a Question
Third-party tested · Purity ≥99% · For laboratory research use only.
Purity
≥99%
Form
Powder (lyophilized blend)
Available sizes
5/5mg

In this blend

Mechanism of Action

Modified GRF (1-29) binds the GHRH receptor, a Gs-coupled receptor that raises cAMP in pituitary somatotrophs. Ipamorelin binds GHS-R1a, which signals through Gq and intracellular calcium. Published pituitary studies report that co-activation of these two pathways produces a greater growth hormone response than either alone, which is why GHRH analog plus GHRP combinations are studied together.

Research Areas

  • ●GHRH and ghrelin receptor co-activation
  • ●Growth hormone pulsatility models
  • ●Pituitary somatotroph signaling
  • ●Secretagogue combination studies

Selected References

  • Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561.

Related Products

GHK-Cu / KPV research peptide vialNew Exclusive Blend

GHK-Cu / KPV

Purity
≥99%
Size
60mg
Form
Powder
$84.00Per Unit
GLOW research peptide vialBlend

GLOW

Purity
99%
Size
70mg
Form
Powder
$118.00Per Unit
KLOW research peptide vialBlend

KLOW

Purity
99%
Size
80mg
Form
Powder
$139.00Per Unit
Lipo-B B12 research peptide vialBlend

Lipo-B B12

Purity
≥99%
Size
10ml
Form
USP
$84.00Per Unit